News Image

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

Provided By GlobeNewswire

Last update: Dec 4, 2024

Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons (four single use doses) of neffy® (epinephrine nasal spray) 2mg for use in emergency treatment of allergic reactions including anaphylaxis

Read more at globenewswire.com

ARS PHARMACEUTICALS INC

NASDAQ:SPRY (12/19/2025, 8:16:50 PM)

After market: 10.49 0 (0%)

10.49

+0.67 (+6.82%)



Find more stocks in the Stock Screener

Follow ChartMill for more